Press Releases

Date	Title	View
06/30/21	Summary Toggle Horizon Therapeutics plc to Host Virtual R&D Day on Sept. 29, 2021	PDF Version
06/29/21	Summary Toggle Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating HZN-7734 for the Treatment of Systemic Lupus Erythematosus	PDF Version
06/28/21	Summary Toggle Gail Devers, Three-Time Olympic Gold Medalist, Partners with the Graves’ Community to FOCUS on Thyroid Eye Disease	PDF Version
06/21/21	Summary Toggle Arrowhead Pharmaceuticals and Horizon Therapeutics Announce Collaboration to Develop RNAi Therapeutic for Uncontrolled Gout	PDF Version
06/18/21	Summary Toggle Horizon Therapeutics plc Announces Multiple Presentations on Neuromyelitis Optica Spectrum Disorder (NMOSD) at the 7th Congress of the European Academy of Neurology (EAN)	PDF Version
06/17/21	Summary Toggle Horizon Therapeutics plc Announces Purchase of Manufacturing Facility to Support Growth of On-Market Rare Disease and Pipeline Biologics	PDF Version
06/02/21	Summary Toggle Horizon Therapeutics plc Presents New Data on Robust Pipeline at EULAR European Congress of Rheumatology	PDF Version
05/27/21	Summary Toggle Horizon Therapeutics plc Initiates ADVANCE Trial Evaluating KRYSTEXXA® (pegloticase injection) with Methotrexate for People Who Previously Developed Anti-Drug Antibodies on KRYSTEXXA Monotherapy	PDF Version
05/24/21	Summary Toggle Horizon Therapeutics plc to Participate in Upcoming Investor Conferences	PDF Version
05/21/21	Summary Toggle Horizon Therapeutics plc Highlights Expanding R&D Efforts with Data Presentations at the EULAR European Congress of Rheumatology	PDF Version